Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761290 · ClinicalTrials.gov registry record
Glucose Homeostasis in Pseudohypoparathyroidism
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- 14
- Enrollment target
NCT03761290 is a clinical trial that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT03761290 was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
It is increasingly recognized that Pseudohypoparathyroidism type 1A (PHP1A) is associated with an increased risk of type 2 diabetes but the mechanism is unknown. In this pilot study we will assess β-cell function in patients with PHP1A and pseudopseudohypoparathyroidism PPHP.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-06-19 |
| Est. Completion | 2021-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03761290
The ClinicalTrials.gov registry entry for NCT03761290 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03761290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03761290 about?
NCT03761290 is a clinical study titled "Glucose Homeostasis in Pseudohypoparathyroidism". It is increasingly recognized that Pseudohypoparathyroidism type 1A (PHP1A) is associated with an increased risk of type 2 diabetes but the mechanism is unknown. In this pilot study we will assess β-cell function in patients with PHP1A and pseudopseudohypoparathyroidism PPHP.
What is the current status of trial NCT03761290?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2019-06-19. Estimated completion is 2021-04-30.
Who is sponsoring clinical trial NCT03761290?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.